Research company Research Centers of America (RCA) said on Tuesday that it is recruiting volunteers to participate in the clinical investigations of COVID-19 vaccines by several big companies under Operation Warp Speed, the Federal Government protocol and US FDA.
The RCA's medical director Dr Howard Schwartz participated in a conference with vice president Mike Pence, school leaders and members of the Miller School of Medicine, along with several other researchers working together to end the battle against COVID-19.
RCA will recruit between 300 and 500 participants solely for the Moderna study, under which, approximately 30,000 participants are expected to enroll in the US. The randomized, placebo-controlled study is expected to investigate a mRNA-1273 dose of 100 µg. The primary objective will be prevention of symptomatic COVID-19 disease.
To ensure the safety and ongoing monitoring of study participants, the data will be reviewed by an independent Data and Safety Monitoring Board organized by NIAID throughout the study, concluded RCA.
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer